What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs

REFERENCES

• Alton K. B., Kosoglou T., Baker S., Affrime M. B., Cayen M. N., Patrick J. E. Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin. Ther. 1998; 20(2)307–323
   PubMed Web of Science ®Google Scholar
• Argenti D., Jensen B. K., Hensel R., Bordeaux K., Schleimer R., Bickel C., Heald D. A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration. J. Clin. Pharmacol. 2000; 40(7)770–780
   PubMed Web of Science ®Google Scholar
• Assandri A., Perazzi A., Ferrari P., Martinelli E., Ripamonti A., Tarzia G., Tuan G. Metabolic fate of zetidoline, a new neuroleptic agent, in man. Nauyn. Schmied. Arch. Pharmacol. 1985; 328(3)341–347
   PubMed Web of Science ®Google Scholar
• Attar M., Yu D., Ni J., Yu Z., Ling K. A. J., Tang-Liu D. D. S. Disposition and biotransformation of the acetylenic retinoid tazarotene in humans. J. Pharm. Sci. 2005; 94(10)2246–2255
   PubMed Web of Science ®Google Scholar
• Baker S. D., Wirth M., Statkevich P., Reidenberg P., Alton K., Sartorius S. E., Dugan M., Cutler D., Batra V., Grochow L. B., Donehower R. C., Rowinsky E. K. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res. 1999; 5(2)309–317
   PubMed Web of Science ®Google Scholar
• Balani S. K., Woolf E. J., Hoagland V. L., Sturgill M. G., Deutsch P. J., Yeh K. C., Lin J. H. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab. Dispos. 1996; 24(12)1389–1394
   PubMed Web of Science ®Google Scholar
• Balani S. K., Xu X., Pratha V., Koss M. A., Amin R. D., Dufresne C., Miller R. R., Arison B. H., Doss G. A., Chiba M., Freeman A., Holland S. D., Schwartz J. I., Lasseter K. C., Gertz B. J., Isenberg J. I., Rogers J. D., Lin J. H., Baillie T. A. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab. Dispos. 1997; 25(11)1282–1287
   PubMed Web of Science ®Google Scholar
• Barbhaiya R. H., Dandekar K. A., Greene D. S. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. Drug Metab. Dispos. 1996; 24(1)91–95
   PubMed Web of Science ®Google Scholar
• Barbhaiya R. H., Knupp C. A., Forgue S. T., Matzke G. R., Halstenson C. E., Opsahl J. A., Pittman K. A. Disposition of the cephalosporin cefepime in normal and renally impaired subjects. Drug Metab. Dispos. 1991; 19(1)68–73
   PubMed Web of Science ®Google Scholar
• Beale P., Judson I., Hanwell J., Berry C., Aherne W., Hickish T., Martin P., Walker M. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother. Pharmacol. 1998; 42: 71–76
   PubMed Web of Science ®Google Scholar
• Beumer J. H., Beijnen J. H., Schellens J. H. M. Mass balance studies, with a focus on anticancer drugs. Clin. Pharmacokinet. 2006; 45: 33–58
   PubMed Web of Science ®Google Scholar
• Beumer J. H., Rademaker-Lakhai J. M., Rosing H., Lopez-Lazaro L., Beijnen J. H., Schellens J. H. M. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Inv. New Drugs 2005; 23(5)429–436
   PubMed Web of Science ®Google Scholar
• Brunner M., Kletter K., Assandri A., Corrado M. E., Eichler H. G., Mueller M. Pharmacokinetic and mass balance study of unlabelled and 14C-labelled emedastine difumarate in healthy volunteers. Xenobiotica 2002; 32(9)761–770
   PubMed Web of Science ®Google Scholar
• Bryce T. A., Chamberlain J., Hillbeck D., Macdonald C. M. Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers. Arz.-Forsch. 1989; 39(4)512–517
   Google Scholar
• Brynne N., Stahl M. M. S., Hallen B., Edlund P. O., Palmer L., Hoglund P., Gabrielsson J. Pharmacokinetics and pharmacodynamics of tolterodine in man. A new drug for the treatment of urinary bladder overactivity. Int. J. Clin. Pharmacol. Ther. 1997; 35(7)287–295
   PubMed Web of Science ®Google Scholar
• Bu H. Z., Pool W. F., Wu E. Y., Raber S. R., Amantea M. A., Shetty B. V. Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab. Dispos. 2004; 32(7)689–698
   PubMed Web of Science ®Google Scholar
• Caldwell G. W., Wu W. N., Masucci J. A. Evaluation of the absorption, excretion and metabolism of [14C]etoperidone in man. Xenobiotica 2001; 31(11)823–839
   PubMed Web of Science ®Google Scholar
• Caldwell G. W., Wu W. N., Masucci J. A., McKown L. A., Gauthier D., Jones W. J., Leo G. C., Maryanoff B. E. Metabolism and excretion of the antiepileptic/antimigraine drug, topiramate in animals and humans. Eur. J. Drug Metab. Pharmacokinet. 2005; 30(3)151–164
   PubMed Web of Science ®Google Scholar
• Cocquyt V., Kline W. F., Gertz B. J., Van Belle S. J. P., Holland S. D., DeSmet M., Quan H., Vyas K. P., Zhang K. E., De Greve J., Porras A. G. Pharmacokinetics of intravenous alendronate. J. Clin. Pharmacol. 1999; 39(4)385–393
   PubMed Web of Science ®Google Scholar
• Colburn W. A., Vane F. M., Bugge C. J. L., Carter D. E., Bressler R., Ehmann C. W. Pharmacokinetics of 14C-isotretinoin in healthy volunteers and volunteers with biliary T-tube drainage. Drug Metab. Dispos. 1985; 13(3)327–332
   PubMed Web of Science ®Google Scholar
• Cook C. S., Ames G. B., Smith M. E., Kowalski K. G., Karim A. Absorption and disposition of a new antiarrhythmic agent bidisomide in man. Pharm. Res. 1993; 10(11)1675–1682
   PubMed Web of Science ®Google Scholar
• Coombes J. D. Metabolism of cefotaxime in animals and humans. Rev. Infect. Dis. 1982; 4(Suppl.)325–332
   Google Scholar
• Cox P. J., Ryan D. A., Hollis F. J., Harris A. M., Miller A. K., Vousden M., Cowley H. Absorption, disposition and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer in humans. Drug Metab. Dispos. 2000; 28: 772–780
   PubMed Web of Science ®Google Scholar
• Crammer J. L., Scott B., Woods H., Rolfe B. Metabolism of 14C-imipramine. I. Excretion in rat and man. Psychopharmacologica 1968; 12: 263–277
   PubMed Web of Science ®Google Scholar
• Dain J. G., Nicoletti J., Ballard F. Biotransformation of clozapine in humans. Drug Metab. Dispos. 1997; 25: 603–609
   PubMed Web of Science ®Google Scholar
• Dalgaard L., Larsen C. Metabolism and excretion of citalopram in man: identification of O‐acyl- and N-glucuronides. Xenobiotica 1999; 29(10)1033–1041
   PubMed Web of Science ®Google Scholar
• Dalrymple P. D., Nicholls P. J. Elimination of radioactivity in man following oral 14C‐aminoglutethimide. IRCS Med. Sci. 1984; 12(1)48–49
   Google Scholar
• Davi H., Carayon A., Berthet D., Cautreels W., Dommisse R., Faiez Zannad M. D. Identification of urinary metabolites of penticainide in the rat, dog, baboon and man. Biomed. Env. Mass Spec. 1986; 13(10)559–568
   PubMedGoogle Scholar
• Davies B., Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993; 10: 1093–1095
   PubMed Web of Science ®Google Scholar
• Delbressine L. P. C., Moonen M. E. G., Kaspersen F. M., Wagenaars G. N., Jacobs P. L., Timmer C. J., Paanakker J. E., van Hal H. J. M., Voortman G. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin. Drug Invest. 1998; 15: 45–55
   PubMed Web of Science ®Google Scholar
• Denissen J. F., Grabowski B. A., Johnson M. K., Buko A. M., Kempf D. J., Thomas S. B., Surber B. W. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538)in rats, dogs, and humans. Drug Metab. Dispos. 1997; 25(4)489–501
   PubMed Web of Science ®Google Scholar
• de Vries P. J., Oosterhuis B., van Boxtel C. J. Single-dose pharmacokinetics of chloroquine and its main metabolite in healthy volunteers. Drug Invest. 1994; 8: 143–149
   Google Scholar
• Durand A., Thenot J. P., Bianchetti G., Morselli P. L. Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab. Rev. 1992; 24(2)239–266
   PubMed Web of Science ®Google Scholar
• Durham S. L., Hoke J. F., Chen T. M. Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. Drug Metab. Dispos. 1993; 21(3)480–484
   PubMed Web of Science ®Google Scholar
• Eckert H. G., Badian M. J., Gantz D., Kellner H. M., Volz M. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. Arz.-Forsch. 1984; 34(10B)1435–1447
   Google Scholar
• Edwall B., Arvidsson A., Lake-Bakaar D., Lanbeck-Vallen K., Yisak W. Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. Drug Metab. Dispos. 1993; 21(1)171–177
   PubMed Web of Science ®Google Scholar
• Efthymiopoulos C., Strolin Benedetti M., Sassella D., Boobis A., Davies D. Pharmacokinetics of [14C]FCE 22891, a penem antibiotic, following oral administration to healthy volunteers. Antimic. Agents Chemother. 1992; 36(9)1958–1963
   PubMed Web of Science ®Google Scholar
• Egger H., Kochak G., Robertson P., Iannucci R., Rufino F. A., Stancato F. Physiological disposition of CGS 16617 in rat, dog, and man. Drug Metab. Dispos. 1989; 17(6)669–672
   PubMed Web of Science ®Google Scholar
• Ericsson H., Hamren B., Bergstrand S., Elebring M., Fryklund L., Heijer M., Oehman K. P. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor a/g agonist, after a single oral and intravenous dose in humans. Drug Metab. Dispos. 2004; 32(9)923–929
   PubMed Web of Science ®Google Scholar
• Eriksson B., Brorsson A. K., Ottersgard H. G., Sjodin T., Gunnarsson P. O. Pharmacokinetics of 14C-delmopinol in the healthy male volunteer. Xenobiotica 1998; 28(11)1075–1081
   PubMed Web of Science ®Google Scholar
• Ferrero J. L., Bopp B. A., Marsh K. C., Quigley S. C., Johnson M. J., Anderson D. J., Lamm J. E., Tolman K. G., Sanders S. W., Cavanaugh J. H. Metabolism and disposition of clarithromycin in man. Drug Metab. Dispos. 1990; 18(4)441–446
   PubMed Web of Science ®Google Scholar
• Filer C. W., Allen G. D., Brown T. A., Fowles S. E., Hollis F. J., Mort E. E., Prince W. T., Ramji J. V. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica 1994; 24(4)357–368
   PubMed Web of Science ®Google Scholar
• Fischer V., Baldeck J. P., Tse F. L. S. Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab. Dispos. 1992; 20(4)603–607
   PubMed Web of Science ®Google Scholar
• Franklin R. A., Norris R., Shepherd N. W., Rhenius S. T. Preliminary studies on the fate of 14C-fentiazac in man. Xenobiotica 1984; 14(12)955–960
   Web of Science ®Google Scholar
• Franklin R. A., Robson P., Stevenson D. Studies on the metabolism of the new antihypertensive agent, indoramin, in man. Eur. J. Clin. Pharmacol. 1983; 24(5)629–634
   PubMed Web of Science ®Google Scholar
• Fromson J. M., Pearson S., Bramah S. The metabolism of tamoxifen (ICI, 46, 474) part II: In female patients. Xenobiotica 1973; 3: 711–714
   PubMed Web of Science ®Google Scholar
• Garner R. C., Goris I., Laenen A. A. E., Vanhoutte E., Meuldermans W., Gregory S., Garner J. V., Leong D., Whattam M., Calam A., Snel C. A. W. Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab. Dispos. 2002; 30(7)823–830
   PubMed Web of Science ®Google Scholar
• Grindel J. M., O'Neill P. J., Yorgey K. A., Schwartz M. H., McKown L. A., Migdalof B. H., Wu W. N. The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. Drug Metab. Dispos. 1980; 8(5)343–348
   PubMed Web of Science ®Google Scholar
• Grislain L., Gele P., Bertrand M., Luijten W., Bromet N., Salvadori C., Kamoun A. The metabolic pathways of tianeptine, a new antidepressant in healthy volunteers. Drug Metab. Dispos. 1990; 18: 804–808
   PubMed Web of Science ®Google Scholar
• Gschwind H. P., Pfaar U., Waldmeier F., Zollinger M., Sayer C., Zbinden P., Hayes M., Pokorny R., Seiberling M., Ben-Am M., Peng B., Gross G. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab. Dispos. 2005; 33(10)1503–1512
   PubMed Web of Science ®Google Scholar
• Halpin R. A., Porras A. G., Geer L. A., Davis M. R., Cui D., Doss G. A., Woolf E., Musson D., Matthews C., Mazenko R., Schwartz J. I., Lasseter K. C., Vyas K. P., Baillie T. A. The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metab. Dispos. 2002; 30(6)684–693
   PubMed Web of Science ®Google Scholar
• Harrison M. P., Haworth S. J., Moss S. R., Wilkinson D. M., Featherstone A. The disposition and metabolic fate of 14C-meropenem in man. Xenobiotica 1993; 23(11)1311–1323
   PubMed Web of Science ®Google Scholar
• Heller D. P., Burke S. K., Davidson D. M., Donovan J. M. Absorption of colesevelam hydrochloride in healthy volunteers. Ann. Pharmacother. 2002; 36(3)398–403
   PubMed Web of Science ®Google Scholar
• Howell S. R., Husbands G. E. M., Scatina J. A., Sisenwine S. F. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993; 23(4)349–359
   PubMed Web of Science ®Google Scholar
• Huempel M., Krause W., Hoyer G. A., Wendt H., Pommerenke G. The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man. Eur. J. Drug Metab. Pharmacokinet. 1984; 9(4)347–357
   PubMed Web of Science ®Google Scholar
• Iyer R. A., Mitroka J., Malhotra B., Bonacorsi S., Waller S. C., Rinehart J. K., Roongta V. A., Kripalani K. Metabolism of [14C] omapatrilat, a sulphydryl-containing vasopeptidase inhibitor in humans. Drug Metab. Dispos. 2001; 29: 60–69
   PubMed Web of Science ®Google Scholar
• Johnson K., Shah A., Jaw-Tsai S., Baxter J., Prakash C. Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers. Drug Metab. Dispos. 2003; 31(1)76–87
   PubMed Web of Science ®Google Scholar
• Jorga K., Fotteler B., Heizmann P., Gasser R. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-o-methyltransferase. Br. J. Clin. Pharmacol. 1999; 48: 513–520
   PubMed Web of Science ®Google Scholar
• Joshi A. S. Elimination pathways of [14C]losoxantrone in four cancer patients. Drug Metab. Dispos. 2001; 29(2)96–99
   PubMed Web of Science ®Google Scholar
• Judson I. R., Beale P. J., Trigo J. M., Aherne W., Crompton T., Jones D., Bush E., Reigner B. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest. New Drugs. 1999; 17(1)49–56
   PubMed Web of Science ®Google Scholar
• Kadar D., Fecycz T. D., Kalow W. The fate of orally administered [4–14C]phenytoin in two healthy male volunteers. Can. J. Physiol. Pharmacol. 1983; 61(4)403–407
   PubMed Web of Science ®Google Scholar
• Kassahun K., Mattiuz E., Nyhart E., Obermeyer B., Gillespie T., Murphy A., Goodwin R. M., Tupper D., Callaghan J. T., Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos. 1997; 25(1)81–93
   PubMed Web of Science ®Google Scholar
• Klunk L. J., Ringel S., Neiss E. S. The disposition of 14C-indapamide in man. J.Clin. Pharmacol. 1983; 23(8–9)377–384
   PubMed Web of Science ®Google Scholar
• Klunk L. J., Riska P. S., Maynard D. E. The disposition and metabolism of 14C-tiaramide.hydrochloride in man. Drug Metab. Dispos. 1982; 10(3)241–245
   PubMed Web of Science ®Google Scholar
• Kollias N., Baqer A. On the assessment of melanin in human skin in vivo. Photochem. Photobiol. 1986; 43(1)49–54
   PubMed Web of Science ®Google Scholar
• Krieter P., Flannery B., Musick T., Gohdes M., Martinho M., Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimic. Agents Chemother. 2004; 48(9)3543–3551
   PubMed Web of Science ®Google Scholar
• Kripalani K. J., McKinstry D. N., Singhvi S. M., Wilard D. A., Vukovich R. A., Migdalof B. H. Disposition of captopril in normal subjects. Clin. Pharmacol. Ther. 1980; 27: 636–641
   PubMed Web of Science ®Google Scholar
• Lantz R. J., Gillespie T. A., Rash T. J., Kuo F., Skinner M., Kuan H. Y., Knadler M. P. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab. Dispos. 2003; 31(9)1142–1150
   PubMed Web of Science ®Google Scholar
• Larsson B., Tjalve H. Studies on the mechanism of drug-binding to melanin. Biochem. Pharmacol. 1979; 28: 1181–1187
   PubMed Web of Science ®Google Scholar
• Latini R., Tognoni G., Kates R. E. Clinical pharmacokinetics and amiodarone. Clin. Pharmacokinet. 1984; 9: 136–156
   PubMed Web of Science ®Google Scholar
• Lau D. T. W., Kalafsky G., Tse F. L. S. The effect of food on the absorption of 14C-SDZ FOX 988, an antidiabetic agent, in healthy human volunteers. Biopharm. Drug Dispos. 1995; 16(3)191–200
   PubMed Web of Science ®Google Scholar
• Leblanc B., Jezequel S., Davies T., Hanton G., Taradach C. Binding of drugs to eye melanin is not predictive of ocular toxicity. Reg. Toxicol. Pharmacol. 1998; 28(2)124–132
   PubMed Web of Science ®Google Scholar
• Lemberger L., Bergstrom R. F., Wolen R. L., Farid N. A., Enas G. G., Aronoff G. R. Fluoxetine: clinical pharmacology and physiologic disposition. J. Clin. Psych. 1985; 46(3, Sec. 2)14–19
   Web of Science ®Google Scholar
• Leopold G., Pabst J., Ungethuem W., Buehring K. U. Basic pharmacokinetics of bisoprolol, a new highly beta1-selective adrenoceptor antagonist. J. Clin.Pharmacol. 1986; 26(8)616–621
   PubMed Web of Science ®Google Scholar
• Lin C. C., Chung M., Gural R., Schuessler D., Kim H. K., Radwanski E., Marco A., DiGiore C., Symchowicz S. Pharmacokinetics and metabolism of rosaramicin in humans. Antimic. Agents Chemother. 1984; 26(4)522–526
   PubMed Web of Science ®Google Scholar
• Lins R., Broekhuysen J., Necciari J., Deroubaix X. Pharmacokinetic profile of 14C-labeled clopidogrel. Sem. Thrombosis Hemostasis 1999; 25(Suppl. 2)29–33
   PubMed Web of Science ®Google Scholar
• Mahon G. J., Anderson H. R., Gardiner T. A., McFarlane S., Archer D. B., Stitt A. W. Chloroquine causes lysosomal dysfunction in neural retina and RPE: Implications for retinopathy. Curr. Eye Res. 2004; 28: 277–284
   PubMed Web of Science ®Google Scholar
• Mangold J. B., Gu H., Rodriguez L. C., Bonner J., Dickson J., Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab. Dispos. 2004; 32(5)566–571
   PubMed Web of Science ®Google Scholar
• Mangold J. B., Schran H. F., Tse F. L. S. Pharmacokinetics and metabolism of cyclosporin G in humans. Drug Metab. Dispos. 1994; 22(6)873–879
   PubMed Web of Science ®Google Scholar
• Mannens G., Huang M. L., Meuldermans W., Hendrickx J., Woestenborghs R., Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Dispos. 1993; 21(6)1134–1141
   PubMed Web of Science ®Google Scholar
• Martin P. D., Warwick M. J., Dane A. L., Hill S. J., Giles P. B., Phillips P. J., Lenz E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Ther. 2003; 25(11)2822–2835
   PubMed Web of Science ®Google Scholar
• Massarella J. W., Loh A. C., Williams T. H., Szuna A. J., Sandor D., Bressler R., Leinweber F. J. The disposition and metabolic fate of 14C-cibenzoline in man. Drug Metab. Dispos. 1986; 14(1)59–64
   PubMed Web of Science ®Google Scholar
• Maurer G., Schreier E., Delaborde S., Nufer R., Shukla A. P. Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism. Eur. J. Drug Metab. Pharmacokinet. 1983; 8(1)51–62
   PubMed Web of Science ®Google Scholar
• McDowell J. A., Chittick G. E., Ravitch J. R., Polk R. E., Kerkering T. M., Stein D. S. Pharmacokinetics of [14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: A mass balance study. Antimic. Agents Chemother. 1999; 43(12)2855–2861
   PubMed Web of Science ®Google Scholar
• McKillop D., Boyle G. W., Cockshott I. D., Jones D. C., Phillips P. J., Yates R. A. Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 1993; 23(11)1241–1253
   PubMed Web of Science ®Google Scholar
• McQuinn R. L., Quarfoth G. J., Johnson J. D., Banitt E. H., Pathre S. V., Chang S. F., Ober R. E., Conard G. J. Biotransformation and elimination of 14C-flecainide acetate in humans. Drug Metab. Dispos. 1984; 12(4)414–420
   PubMed Web of Science ®Google Scholar
• Meuldermans W., Hendrickx J., Woestenborghs R., Van Peer A., Lauwers W., De Cree J., Heykants J. Absorption, metabolism and excretion of ketanserin in man after oral administration. Arz.-Forsch. 1988; 38(6)789–794
   Google Scholar
• Meuldermans W., Hurkmans R., Swysen E., Hendrickx J., Michiels M., Lauwers W., Heykants J. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur. J. Drug Metab. Pharmacokinet. 1981; 6(1)49–60
   PubMedGoogle Scholar
• Midgley I., Chasseaud L. F., Taylor T., Darragh A. The absorption and excretion of 14C-lofexidine hydrochloride in man. Arz.-Forsch. 1982; 32(8A)972–975
   Google Scholar
• Midgley I., Fowkes A. G., Darragh A., Lambe R., Chasseaud L. F., Taylor T. The metabolic fate of the anti-androgenic agent, oxendolone, in man. Steroids 1983; 41(4)521–536
   PubMed Web of Science ®Google Scholar
• Mitchell S. C., Idle J. R., Smith R. L. The metabolism of [14C]cimetidine in man. Xenobiotica 1982; 12(5)283–292
   PubMed Web of Science ®Google Scholar
• Miyamoto G., Sasabe H., Tominaga N., Uegaki N., Tominaga M., Shimizu T. Metabolism of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl0-1-piperazinyl]-2(1H)-quinolinone (OPC-8212) in the rat, mouse, dog, monkey, and human. Xenobiotica 1988; 18(10)1143–1155
   PubMed Web of Science ®Google Scholar
• Molimard M., Diquet B., Strolin Benedetti M. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fund. Clin. Pharmacol. 2004; 18(4)399–411
   PubMed Web of Science ®Google Scholar
• Moller A., Iwasaki K., Kawamura A., Teramura Y., Shiraga T., Hata T., Schafer A., Undre N. A. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab. Dispos. 1999; 27(6)633–636
   PubMed Web of Science ®Google Scholar
• Morishita N., Tomono Y., Hasegawa J., Yuzuriha T., Giese U. Absorption, elimination and metabolic fate of bunazosin in 3 healthy male volunteers. Drug Invest. 1993; 5(6)296–301
   Web of Science ®Google Scholar
• Mroszczak E. J., Lee F. W. Tiopinac absorption, distribution, excretion, and pharmacokinetics in man and animals. Drug Metab. Dispos. 1980; 8(6)415–421
   PubMed Web of Science ®Google Scholar
• Murayama N., McMahon H., Young C. G., McCracken N. W., Okamura Y., Hakusui H., Tanaka M. Pharmacokinetics of the anticoagulant 14C-DX-9065a in the healthy male volunteer after a single intravenous dose. Xenobiotica 2000; 30(5)515–521
   PubMed Web of Science ®Google Scholar
• Nagai J., Tanaka H., Nakanishi N., Murakami T., Takano M. Role of megalin in renal handling of aminoglycosides. Am. J. Physiol. 2001; 281: F337–F344
   PubMed Web of Science ®Google Scholar
• Nave R., Bethke T. D., Van Marle S. P., Zech K. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokinet. 2004; 43(7)479–486
   PubMed Web of Science ®Google Scholar
• Neugebauer G., Akpan W., Von Moellendorff E., Neubert P., Reiff K. Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol. 1987; 10(Suppl. 11)S85–S88
   PubMedGoogle Scholar
• Norrby S. R., Rogers J. D., Ferber F., Jones K. H., Zacchei A. G., Weidner L. L., Demetriades J. L., Gravallese D. A., Hsieh J. Y. K. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimic. Agents Chemother. 1984; 26(5)707–714
   PubMed Web of Science ®Google Scholar
• Ono C., Yamado M., Tanaka M. Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: Binding characteristics of chloroquine related radioactivity to melanin in vivo. J. Pharm. Pharmacol. 2003; 55: 1647–1654
   PubMed Web of Science ®Google Scholar
• Osman M., Chandrasekaran A., Chan K., Scatina J., Ermer J., Cevallos W., Sisenwine S. F. Metabolic disposition of 14C-bromfenac in healthy male volunteers. J. Clin. Pharmacol. 1998; 38(8)744–752
   PubMed Web of Science ®Google Scholar
• Patrick J. E., Kosoglou T., Stauber K. L., Alton K. B., Maxwell S. E., Zhu Y., Statkevich P., Iannucci R., Chowdhury S., Affrime M., Cayen M. N. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab. Dispos. 2002; 30(4)430–437
   PubMed Web of Science ®Google Scholar
• Paulson S. K., Hribar J. D., Liu N. W. K., Hajdu E., Bible R. H., Piergies A., Karim A. Metabolism and excretion of [14C]celecoxib in healthy male volunteers. Drug Metab. Dispos. 2000; 28(3)308–314
   PubMed Web of Science ®Google Scholar
• Peck R. W., Wootton R., Lee D. R., Jackson S. H. D., Posner J. The bioavailability and disposition of 1-(b-D-arabinofuranosyl)-5-(1-propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent. Br. J. Clin. Pharmacol. 1995; 39(2)143–149
   PubMed Web of Science ®Google Scholar
• Peeters P. A. M., Van Lier J. J., Van de Merbel N., Oosterhuis B., Wieling J., Jonkman J. H. G., Klessing K., Biber A. Pharmacokinetics of [14C]-labeled losigamone and enantiomers after oral administration to healthy subjects. Eur. J. Drug Metab. Pharmacokinet. 1998; 23(1)45–53
   PubMed Web of Science ®Google Scholar
• Pentikainen P. J., Neuvonen P. J., Penttila A. Pharmacokinetics and pharmacodynamics of glipizide in health volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 1983; 21(2)98–107
   PubMed Web of Science ®Google Scholar
• Pentikainen P. J., Penttila A., Neuvonen P. J., Khalifah R. G., Hignite C. E. Human metabolism of tolfenamic acid. I. Isolation, preliminary characterization and pharmacokinetics of tolfenamic acid and its metabolites. Eur. J.Drug Metab. Pharmacokinet. 1982; 7(4)259–267
   PubMed Web of Science ®Google Scholar
• Pieniaszek H. J., Davidson A. F., Chaney J. E., Shum L., Robinson C. A., Mayersohn M. Human moricizine metabolism. II. Quantification and pharmacokinetics of plasma and urinary metabolites. Xenobiotica 1999; 29(9)945–955
   PubMed Web of Science ®Google Scholar
• Plozza-Nottebrock H., Stoeckel K., Vergin H. Pharmacokinetics of metioprim (Ro 12–6995) in humans. Curr. Chemother. Immunother. (Proc. 12th Int. Congr. Chemother.) 1982; 2: 946–947
   Google Scholar
• Pool W. F., Reily M. D., Bjorge S. M., Woolf T. F. Metabolic disposition of the cognition activator tacrine in rats, dogs, and humans. Species comparisons. Drug Metab. Dispos. 1997; 25: 590–597
   PubMed Web of Science ®Google Scholar
• Ray J. E., Wade D. N. The pharmacokinetics and metabolism of 14C-carprofen in man. Biopharm. Drug Dispos. 1982; 3(1)29–38
   PubMed Web of Science ®Google Scholar
• Reasor M. J., Kacew S. Drug induced phospholipidosis: Are there functional consequences?. Exp. Biol. Med. 2001; 226: 825–830
   PubMed Web of Science ®Google Scholar
• Regaardh C. G., Andersson T., Lagerstroem P. O., Lundborg P., Skaanberg I. The pharmacokinetics of omeprazole in humans - a study of single intravenous and oral doses. Ther. Drug Monit. 1990; 12(2)163–172
   PubMed Web of Science ®Google Scholar
• Reith K., Keung A., Toren P. C., Cheng L., Eller M. G., Weir S. J. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab. Dispos. 1988; 26(8)732–738
   Google Scholar
• Reith M. K., Sproles G. D., Cheng L. K. Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist. Drug Metab. Dispos. 1995; 23(8)806–812
   PubMed Web of Science ®Google Scholar
• Renwick A. G., Pettet J. L., Gruchy B., Corina D. L. The fate of [14C]trithiozine in man. Xenobiotica 1982; 12(5)329–343
   PubMed Web of Science ®Google Scholar
• Riley P., Figary P. C., Entwisle J. R., Roe A. L., Thompson G. A., Ohashi R., Ohashi N., Moorehead T. J. The metabolic profile of azimilide in man: In vivo and in vitro evaluations. J. Pharm. Sci. 2005; 94(9)2084–2095
   PubMed Web of Science ®Google Scholar
• Riska P., Lamson M., Macgregor T., Sabo J., Hattox S., Pav J., Keirns J. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. 1999; 27(8)895–901
   PubMed Web of Science ®Google Scholar
• Roberts A., Renwick A. G., Sims J., Snodin D. J. Sucralose metabolism and pharmacokinetics in man. Food Chem. Toxicol. 2000; 38(Suppl. 2)S31–S41
   PubMed Web of Science ®Google Scholar
• Rodrigues A. D., Halpin R. A., Geer L. A., Cui D., Woolf E. J., Matthews C. Z., Gottesdiener K. M., Larson P. J., Lasseter K. C., Agrawal N. G. B. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab. Dispos. 2003; 31(2)224–232
   PubMed Web of Science ®Google Scholar
• Roth W., Bauer E., Heinzel G., Cornelissen P. J. G., Van Tol R. G. L., Jonkman J. H. G., Zuiderwijk P. B. M. Zatebradine: Pharmacokinetics of a novel heart-rate-lowering agent after intravenous infusion and oral administration to healthy subjects. J. Pharm. Sci. 1993; 82(1)99–106
   PubMed Web of Science ®Google Scholar
• Roth W., Koss F. W., Hallinan D., Lambe R., Darragh A. Pharmacokinetics of falipamil after intravenous administration to humans. J. Pharm. Sci. 1990; 79(5)415–419
   PubMed Web of Science ®Google Scholar
• Rubio F., Jensen B. K., Henderson L., Garland W. A., Szuna A., Town C. Disposition of [14C]acitretin in humans following oral administration. Drug Metab. Dispos. 1994; 22(2)211–215
   PubMed Web of Science ®Google Scholar
• Rush W. R., Alexander O., Hall D. J., Cairncross L., Dow R. J., Graham D. J. G. The metabolism of nicardipine hydrochloride in healthy male volunteers. Xenobiotica 1986; 16(4)341–349
   PubMed Web of Science ®Google Scholar
• Sadler B. M., Chittick G. E., Polk R. E., Slain D., Kerkering T. M., Studenberg S. D., Lou Y., Moore K. H. P., Woolley J. L., Stein D. S. Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects. J. Clin. Pharmacol. 2001; 41(4)386–396
   PubMed Web of Science ®Google Scholar
• Seaber E., On N., Dixon R. M., Gibbens M., Leavens W. J., Liptrot J., Chittick G., Posner J., Rolan P. E., Peck R. W. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (3 I I C90). Br. J. Clin. Pharmacol. 1997; 43(6)579–587
   PubMed Web of Science ®Google Scholar
• Shah B., Emmons G., Rohatagi S., Martin N. E., Jensen B. K. Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects. Am. J. Ther. 2003; 10(5)356–362
   PubMedGoogle Scholar
• Shumaker R. C., Fantel C., Kelton E., Wong K., Weliky I. Evaluation of the elimination of (14C) felbamate in healthy men. Epiliepsia 1990; 31(5)642
   Google Scholar
• Simons P. J., Cockshott I. D., Douglas E. J., Gordon E. A., Hopkins K., Rowland M. Disposition in male volunteers of a subanesthetic intravenous dose of an oil in water emulsion of 14C-propofol. Xenobiotica 1988; 18(4)429–440
   PubMed Web of Science ®Google Scholar
• Singhvi S. M., Duchin K. L, Morrison R. A., Willard D. A., Everett D. W., Frantz M. Disposition of fosinopril sodium in healthy subjects. Br. J. Clin. Pharmacol. 1988; 25(1)9–15
   PubMed Web of Science ®Google Scholar
• Singhvi S. M., Foley J. E., Willard D. A., Morrison R. A. Disposition of zofenopril calcium in healthy subjects. J. Pharm. Sci. 1990a; 79(11)970–973
   PubMed Web of Science ®Google Scholar
• Singhvi S. M., Pan H. Y., Morrison R. A., Willard D. A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 1990b; 29(2)239–243
   PubMed Web of Science ®Google Scholar
• Sisenwine S. F., Liu A. L., Tio C., Kimmel H., Freeland G. The metabolic disposition of 14C-ciramadol in humans. Xenobiotica 1986; 16(4)335–340
   PubMed Web of Science ®Google Scholar
• Slatter J. G., Schaaf L. J., Sams J. P., Feenstra K. L., Johnson M. G., Bombardt P. A., Cathcart K. S., Verburg M. T., Pearson L. K., Compton L. D., Miller L. L., Baker D. S., Pesheck C. V., Lord R. S. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients. Drug Metab. Dispos. 2000; 28(4)423–433
   PubMed Web of Science ®Google Scholar
• Slatter J. G., Stalker D. J., Feenstra K. L., Welshman I. R., Bruss J. B., Sams J. P., Johnson M. G., Sanders P. E., Hauer M. J., Fagerness P. E., Stryd R. P., Peng G. W., Shobe E. M. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects. Drug Metab. Dispos. 2001; 29(8)1136–1145
   PubMed Web of Science ®Google Scholar
• Slattery J. T., Wilson J. M., Kalhorn T. F., Nelson S. D. Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. Clin. Pharmacol.Ther. 1987; 41: 413–418
   PubMed Web of Science ®Google Scholar
• Smith D. A., Obach R. S. Seeing through the MIST: Abundance vs percentage. commentary on metabolites in safety testing. Drug Metab. Dispos. 2005; 33: 1409–1417
   PubMed Web of Science ®Google Scholar
• Soul-Lawton J., Seaber E., On N., Wootton R., Rolan P., Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimic. Agents Chemother. 1995; 39(12)2759–2764
   PubMed Web of Science ®Google Scholar
• Stoltz R., Parisi S., Shah A., Macciocchi A. Pharmacokinetics, metabolism and excretion of intravenous [14C]-palonosetron in healthy human volunteers. Biopharm. Drug Dispos. 2004; 25(8)329–337
   PubMed Web of Science ®Google Scholar
• Strolin Benedetti M., Plisnier M., Kaise J., Maier L., Baltes E., Arendt C., McCracken N. Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur. J. Clin. Pharmacol. 2001; 57(8)571–582
   PubMed Web of Science ®Google Scholar
• Sunzel M. New Drug Development, Regulatory Paradigms for Clinical Pharamcology and Biopharmaceutics, C.G. Sahajwalla. Marcel Decker, New York 2004; 187–212
   Google Scholar
• Takadoro T., Kobayashi N., Zmudzka B. Z., Ito S., Wakamatsu K., Yamaguchi Y., Korossy K. S., Miller S. A., Beer J. Z., Hearing V. J. UV-Induced DNA damage and melanin content in human skin differing in racial ethnic origin. FASEB J. 2003; 17: 1177–1179
   PubMed Web of Science ®Google Scholar
• Timmer C. J., Ad Sitsen J. M., Delbressine L. P. Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinet. 2000; 38: 461–474
   PubMed Web of Science ®Google Scholar
• Tiseo P. J., Perdomo C. A., Friedhoff L. T. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br. J. Clin. Pharmacol. 1998; 46(Suppl. 1)19–24
   PubMed Web of Science ®Google Scholar
• Toler S. M. Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy. Exp. Biol. Med. 2004; 229: 607–615
   PubMed Web of Science ®Google Scholar
• Toler S. M. Fluphenazine augments retinal oxidative stress. J. Ocular Pharmacol. Therap. 2005; 21: 259–265
   PubMed Web of Science ®Google Scholar
• Tomori E., Horvath G., Patfalusi M., Meszaros S., Vereczkey L. Pharmacokinetic and metabolism studies on girisopam by chromatographic and spectrometric methods in humans. J. Chrom. 1992; 578(1)91–101
   PubMed Web of Science ®Google Scholar
• Toon S., Heimark L. D., Trager W. F., O'Reilly R. A. Metabolic fate of phenprocoumon in humans. J. Pharm Sci. 1985; 74(10)1037–1040
   PubMed Web of Science ®Google Scholar
• Tse F. L. S. Pharmacokinetics in drug discovery and development: nonclinical studies. Pharmacokinetics. Regulatory, Industrial, Academic Perspectives, P. G. Welling, F. L. S. Tse. Marcel Dekker, Inc., New York 1995; 281–334
   Google Scholar
• Tse F. L. S., Jaffe J. M. Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man. Eur. J. Clin. Pharmacol. 1987a; 32(4)361–365
   PubMed Web of Science ®Google Scholar
• Tse F. L. S., Jaffe J. M., Bhuta S. Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fund. Clin. Pharmacol. 1987b; 1(6)479–488
   PubMed Web of Science ®Google Scholar
• Tse F. L. S., Jaffe J. M., Dain J. G. Pharmacokinetics of compound 58–112, a potential skeletal muscle relaxant, in man. J. Clin. Pharmacol. 1984; 24(1)47–57
   PubMed Web of Science ®Google Scholar
• Turcan R. G., Hillbeck D., Hartley T. E., Gilbert P. J., Coe R. A. J., Troke J. A., Vose C. W. Disposition of [14C]velnacrine maleate in rats, dogs, and humans. Drug Metab. Dispos. 1992; 21(6)1037–1047
   Web of Science ®Google Scholar
• van den Bongard H. J. G. D., Plium D., Rosing H., Nan-Offeringa L., Schot M., Ravic M., Schellens J. H. M., Beijnen J. H. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anti-Cancer Drugs 2002; 13(8)807–814
   PubMed Web of Science ®Google Scholar
• van Heiningen P. N. M., Hatorp V., Kramer Nielsen K., Hansen K. T., van Lier J. J., De Merbel N. C., Oosterhuis B., Jonkman J. H. G. Absorption, metabolism and excretion of a single oral dose of 14C-repaglinide during repaglinide multiple dosing. Eur. J. Clin. Pharmacol. 1999; 55(7)521–525
   PubMed Web of Science ®Google Scholar
• van Lier J. J., van Heiningen P. N. M., Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J. Hum. Hyperten. 1997; 11(Suppl. 2)S27–S28
   PubMed Web of Science ®Google Scholar
• Vargay Z., Deutsch T., Szatmari I., Szuts T., Varkonyi T., Kerpel-Fronius S., Eckhardt S. The fate of Drotaverine-Acephyllinate in rat and man. II. Human pharmacokinetics of Drotaverine-14C-Acephyllinate. Eur. J. Drug Metab. Pharmacokinet. 1984; 9(1)17–29
   PubMed Web of Science ®Google Scholar
• Vincent J., Teng R., Dalvie D. K., Friedman H. L. Pharmacokinetics and metabolism of single doses of trovafloxacin. Am. J. Surg. 1998; 176(Suppl 6A)85–135
   Google Scholar
• Vinge E., Midskov C., Arnold E. Pharmacokinetics of 14C-fenflumizole after intravenous administration to man. Acta Pharmacol. Toxicol. 1986; 58(5)355–362
   PubMedGoogle Scholar
• Vitiello B., Buniva G., Bernareggi A., Assandri A., Perazzi A., Fuccella L. M., Palumbo R. Pharmacokinetics and metabolism of premazepam, a new potential anxiolytic, in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 1984; 22(5)273–277
   PubMed Web of Science ®Google Scholar
• Vollmer K. O., Poisson A. Metabolism of thymoxamine. II. Studies with 14C-thymoxamine in man. Eur. J. Drug Metab. Pharmacokinet. 1985; 10(1)71–76
   PubMed Web of Science ®Google Scholar
• Vos R. M. E., Krebbers S. F. M., Verhoeven C. H. J., Delbressine L. P. C. The in vivo human metabolism of tibolone. Drug Metab. Dispos. 2002; 30(2)106–112
   PubMed Web of Science ®Google Scholar
• Vree T. B., Waitzinger J., Hammermaier A., Radhofer-Welte S. Absolute bioavailability, pharmacokinetics, renal, and biliary clearance of distigmine after a single oral dose in comparison to i.v. administration of 14C-distigmine-bromide in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 1999; 37(8)393–403
   PubMed Web of Science ®Google Scholar
• Vyas K. P., Halpin R. A., Geer L. A., Ellis J. D., Liu L., Cheng H., Chavez-Eng C., Matuszewski B. K., Varga S. L., Guiblin A. R., Rogers J. D. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metab. Dispos. 2000; 28(1)89–95
   PubMed Web of Science ®Google Scholar
• Wait J. C. M., Vaccharajani N., Mitroka J., Jemal M., Khan S., Bonacorsi S. J., Rinehart J. K., Iyer R. A. Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans. Drug Metab. Dispos. 2006; 34: 961–970
   PubMed Web of Science ®Google Scholar
• Waldmeier F., Kaiser G., Ackermann R., Faigle J. W., Wagner J., Barner A., Lasseter K. C. The disposition of [14C]-labelled benazepril hydrochloride in normal adult volunteers after single and repeated oral dose. Xenobiotica 1991; 21(2)251–261
   PubMed Web of Science ®Google Scholar
• Walker O., Salako L. A., Alvan G., Ericsson O., Sjoqvist F. S. The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br. J. Clin. Pharmacol. 1987; 23: 295–301
   PubMed Web of Science ®Google Scholar
• Walle T., Hsieh F., DeLegge M. H., Oatis J. E., Walle U. K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004; 32(12)1377–1382
   PubMed Web of Science ®Google Scholar
• Washio T., Kohsaka K., Arisawa H., Masunaga H., Nagatsuka S. I., Satoh Y. Pharmacokinetics and metabolism of radiolabeled SNI-2011, a novel muscarinic receptor agonist, in healthy volunteers: Comprehensive understanding of absorption, metabolism and excretion using radiolabeled SNI-2011. Arz.-Forsch. 2003; 53(2)80–86
   Google Scholar
• Webber C., Roth A., Persiani S., Peard A. J., Makovec F., Kapil R. P., John B. A., Holding J. D., D'Amato M., Cybulski Z. R., Chasseaud L. F., Rovati L. C. Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Xenobiotica 2003; 33(6)625–641
   PubMed Web of Science ®Google Scholar
• Weber C., Gasser R., Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab. Dispos. 1999; 27(7)810–815
   PubMed Web of Science ®Google Scholar
• Weidekamm E., Stoeckel K., Egger H. J., Ziegler W. H. Single-dose pharmacokinetics of Ro 17–2301 (AMA-1080), a monocyclic b-lactam, in humans. Antimic. Agents Chemother. 1984; 26(6)898–902
   PubMed Web of Science ®Google Scholar
• Weil A., Caldwell J., Strolin-Benedetti M. The metabolism and disposition of 14C-fenofibrate in human volunteers. Drug Metab. Dispos. 1990; 18(1)115–120
   PubMed Web of Science ®Google Scholar
• Widman M., Nilsson L. B., Bryske B., Lundstrom J. Disposition of remoxipride in different species. Arz.-Forsch. 1993; 43(3)287–297
   Google Scholar
• Wilson I. D., Fromson J. M., Illing H. P. A., Schraven E. The metabolism of [14C]N-ethoxycarbonyl-3-morpholinosydnone imine (molsidomine) in man. Xenobiotica 1987; 17(1)93–104
   PubMed Web of Science ®Google Scholar
• Winslade N. E., Adelman M. H., Evans E. J., Schentag J. J. Single-dose accumulation pharmacokinetics of tobramycin and netimicin in normal volunteers. Antimicrob. Agents Chemother. 1987; 31: 605–609
   PubMed Web of Science ®Google Scholar
• Winternitz P. F., Dulcire B., Crawley Y. Pharmacokinetics and metabolism of diosmin. Proc. Eur. Congr. Biopharm. Pharmacokinet. 1987; 2: 658–664
   Google Scholar
• Wong B. K., Xu X., Yu S., Lin J. H., Singh R., Sahly Y., Mistry G., Holland S., Waldman S., Musson D., Majumdar A. Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. Xenobiotica 2004; 34(4)379–389
   PubMed Web of Science ®Google Scholar
• Wong F. A., Lloyd J. R., Graden D. W. The metabolism of etintidine in rat, dog, and human. Drug Metab. Dispos. 1990; 18(6)949–953
   PubMed Web of Science ®Google Scholar
• Wong S. L., Awni W. M., Cavanaugh J. H., El-Shourbagy T., Locker C. S., Dube L. M. The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers. Clin. Pharmacokinet. 1995; 29(Suppl2)9–21
   PubMedGoogle Scholar
• Wood S. G., John B. A., Chasseaud L. F., Yeh J., Chung M. The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann. Allergy. 1987; 59(6, Part 2)31–34
   PubMedGoogle Scholar
• Woodworth J. R., DeLong A. F., Fasola A. F., Oldham S. 14C-Isomazole disposition in man after oral administration. Pharm. Res. 1991; 8(11)1413–1417
   PubMed Web of Science ®Google Scholar
• Woodworth J. R., Nyhart E. H., Brier G. L., Wolny J. D., Black H. R. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimic. Agents Chemother. 1992; 36(2)318–325
   PubMed Web of Science ®Google Scholar
• Young G., Ellis W., Ayrton J., Hussey E., Adamkiewicz B. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 2001; 31(8/9)619–632
   PubMed Web of Science ®Google Scholar
• Yuan J. J., Yang D. C., Zhang J. Y., Bible R., Karim A., Findlay J. W. A. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab. Dispos. 2002; 30(9)1013–1021
   PubMed Web of Science ®Google Scholar
• Zhang D., Krishna R., Wang L., Zeng J., Mitroka J., Dai R., Narasimhan N., Reeves R. A., Srinivas N. R., Klunk L. J. Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled maxipost (BMS-204352) in humans. Drug Metab. Dispos. 2005; 33(1)83–93
   PubMed Web of Science ®Google Scholar
• Zhi J., Melia A. T., Funk C., Viger-Chougnet A., Hopfgartner G., Lausecker B., Wang K., Fulton J. S., Gabriel L., Mulligan T. E. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J. Clin. Pharmacol. 1996; 36(11)1006–1011
   PubMed Web of Science ®Google Scholar